<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043537</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH053703</org_study_id>
    <secondary_id>R01MH053703</secondary_id>
    <nct_id>NCT00043537</nct_id>
  </id_info>
  <brief_title>Treatment of Childhood Social Phobia</brief_title>
  <official_title>Treatment of Childhood Social Phobia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Central Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Central Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 4-year study will compare the long-term effectiveness of behavioral treatment,
      fluoxetine (ProzacÂ®), and placebo for treatment of social phobia in children and adolescents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Social phobia affects 3-5 percent of children, and prevalence rises with age. Youth with
      social phobia fear many activities that are part of everyday life and suffer from problems
      such as headaches or stomachaches, panic, avoidance, general anxiety, depression, loneliness,
      and a very restricted range of social relationships. Recent findings indicate a new
      psychosocial treatment called Social Effectiveness Therapy for Children (SET-C) is effective
      in treating children ages 8-11, resulting in reduced emotional distress and improved social
      functioning. Treatment effects have been maintained for up to 6 months. This study will
      examine SET-C in children ages 8-15. Because available data suggest that the drug fluoxetine
      is a promising treatment, SET-C will be compared to fluoxetine in this trial. Durability of
      treatment will be monitored over a 1-year follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Social Phobia</condition>
  <arm_group>
    <arm_group_label>Social Effectiveness Therapy for Children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Social Effectiveness Therapy for Children includes social skills training, peer generalization experiences and exposure therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluoxetine given in 10mg doses, up to 40 mg as tolerated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pill placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules identical to fluoxetine given in &quot;10 mg.&quot; doses up to 40 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Social Effectiveness Therapy for Children (SET-C)</intervention_name>
    <arm_group_label>Social Effectiveness Therapy for Children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <arm_group_label>Fluoxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pill Placebo</intervention_name>
    <arm_group_label>Pill placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of social phobia

        Exclusion Criteria:

          -  Pervasive developmental disorders (PDD)

          -  Schizophrenia

          -  Major Depression

          -  IQ of less than 80

          -  Medical conditions contraindicating use of fluoxetine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maryland Center for Anxiety Disorders</name>
      <address>
        <city>University of Maryland, College Park</city>
        <state>Maryland</state>
        <zip>20742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S. SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2007 Dec;46(12):1622-32.</citation>
    <PMID>18030084</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2002</study_first_submitted>
  <study_first_submitted_qc>August 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2002</study_first_posted>
  <last_update_submitted>July 31, 2013</last_update_submitted>
  <last_update_submitted_qc>July 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Central Florida</investigator_affiliation>
    <investigator_full_name>Deborah Beidel</investigator_full_name>
    <investigator_title>Professor of Psychology</investigator_title>
  </responsible_party>
  <keyword>Phobic Disorders</keyword>
  <keyword>Mutism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phobic Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

